People
Our people are what make Insmed what it is today.
Coming from a broad range of backgrounds and with a variety of technical, analytical and business capabilities, Insmed's staff is working to develop IPLEX into a therapy showing potential for the treatment of Myotonic Muscular Dystrophy (MMD) and Amyotrophic Lateral Sclerosis (ALS), or Lou Gehrig's disease while also developing a new market capability in the area of follow-on biologics, or biosimliars.
- Insmed has an experienced team with proven ability to develop recombinant protein products
- We have more than 600 years of collective experience working with leaders across the biotechnology industry
- Insmed scientists and engineers have experience of working with over 50 therapeutic protein drug products
Insmed's staff of scientists and engineers has been making biologics for years. We are ready to produce these medicines at our state-of-the-art, FDA-approved facilities today.
